NCT03015922

Viral Immunotherapy in Relapsed/Refractory Multiple Myeloma

VIRel: Viral Immunotherapy in Relapsed/Refractory Multiple Myeloma - A Phase I Study to Assess the Safety and Tolerability of REOLYSIN® (Pelareorep) in Combination With Lenalidomide or Pomalidomide

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 4 (actual)
• Sponsor: University of Leeds · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will recruit patients currently receiving either lenalidomide or pomalidomide whose disease is relapsing. This is a dose escalation study and the aim is to determine the maximum tolerated dose (MTD) of REOLYSIN® that can be given in combination with lenalidomide or pomalidomide. The study will also investigate the safety, side effects and effectiveness of this treatment combination. Pomalidomide and lenalidomide will be evaluated separately as two separate groups.

Conditions

• Multiple Myeloma

Interventions

Type	Name	Description
DRUG	Lenalidomide or Pomalidomide	Patients will received either lenalidomide or pomalidomide, depending on which drug they were receiving prior to the trial (they will receive the same as before).
BIOLOGICAL	REOLYSIN	Patients will receive Reolysin alongside either lenalidomide or pomalidomide

Timeline

• Start date: 2017-06-05
• Primary completion: 2021-09-01
• Completion: 2021-10-01
• First posted: 2017-01-10
• Last updated: 2020-01-22

Locations

2 sites across 1 country: United Kingdom